INDV Q2 2024 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$299M+8.3% YoY

Gross Profit

$220M73.6% margin

Operating Income

-$118M-39.5% margin

Net Income

-$97M-32.4% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

+5.3%

Cash Flow

Operating Cash Flow

$88M

Free Cash Flow

$84M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$1.7B

Stockholders' Equity

-$121M

Cash & Equivalents

$302M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$299M	$276M	+8.3%
Gross Profit	$220M	$226M	-2.7%
Operating Income	-$118M	$61M	-293.4%
Net Income	-$97M	$39M	-348.7%